Table 3 Operative and follow-up details
Prostate vol, median (mL) (IQR) | 56 (43–70) |
Index tumour vol, median (mL) (IQR) | 0.75 (0.25–1) |
Time between initial IRE ablation and sRARP (mo), median (IQR) | 42 (21–57) |
Nerve sparing, n (%) | |
Unilateral | 6 (40%) |
Bilateral | 9 (60%) |
None | 0 |
Pelvic lymph node dissection, n (%) | 4 (27%) |
Gleason Grade/ISUP GGG after sRP, n (%) [Index Lesion] | |
3 + 3/1 | 0 |
3 + 4/2 | 8 (53%) |
4 + 3/3 | 1 (7%) |
4 + 4/4 | 3 (20%) |
4 + 5/5 | 3 (20%) |
Gleason Grade/ISUP GGG after sRP, n (%) [Composite] | |
3 + 3/1 | 0 |
3 + 4/2 | 9 (60%) |
4 + 3/3 | 3 (20%) |
4 + 4/4 | 0 |
4 + 5/5 | 3 (20%) |
Surgical margin involvement, n (%) | 1 (7%) |
T stage, n (%) | |
pT2 | 9 (60%) |
pT3a | 6 (40%) |
pT3b | 0 |
Presence of cribriform pattern, n (%) | |
Yes | 5 (33%) |
No | 9 (67%) |
Surgical complications, n (%) (rectal injury, cystotomy, ureteric injury) | 0 |
Blood loss, mL, media (IQR) | 200 (200–250) |
Length of Stay, median | 2 days |
Follow-up (mo) since sRARP, median (IQR) | 20 (15–30) |
Postoperative RT, n (%) | 0 |
Metastasis, n (%) | 0 |
Continence, n (%) | |
Pad free after 3 months | 14 |
Pad free after 6 months | 1 |
Incontinent | 0 |
Erections, n (%) | |
Potent | 5 (33%) |
Potent with PDE-5 inhibitor | 4 (27%) |
Impotent | 6 (40%) |